Dyspnoea and worsening heart failure in patients with acute heart failure: results from the Pre-RELAX-AHF study
نویسندگان
چکیده
منابع مشابه
Dyspnoea and worsening heart failure in patients with acute heart failure: results from the Pre-RELAX-AHF study
AIMS Although dyspnoea is the most common cause of admission for acute heart failure (AHF), more needs to be known about its clinical course and prognostic significance. METHODS AND RESULTS The Pre-RELAX-AHF study randomized 232 subjects with AHF to placebo or four doses of relaxin and evaluated early (6-24 h Likert scale) and persistent [change in visual analogue scale area under the curve (...
متن کاملEffects of serelaxin in subgroups of patients with acute heart failure: results from RELAX-AHF
AIM Patients hospitalized for acute heart failure (AHF) differ with respect of many clinical characteristics which may influence their prognosis and response to treatment. We have assessed possible differences in the effects of serelaxin on dyspnoea relief, 60 Day outcomes and 180 Day mortality across patient subgroups in the RELAX-AHF trial. METHODS AND RESULTS Subgroups were based on pre-sp...
متن کاملWorsening Heart Failure Following Admission for Acute Heart Failure: A Pooled Analysis of the PROTECT and RELAX-AHF Studies.
OBJECTIVES These studies conducted analyses to examine patient characteristics and outcomes associated with worsening heart failure (WHF). BACKGROUND WHF during an admission for acute heart failure (AHF) represents treatment failure and is a potential therapeutic target for clinical trials of AHF. METHODS Individual patient data from the PROTECT (Placebo-Controlled Randomized Study of the S...
متن کاملSerelaxin in acute heart failure patients with preserved left ventricular ejection fraction: results from the RELAX-AHF trial
AIMS Serelaxin is effective in relieving dyspnoea and improving multiple outcomes in acute heart failure (AHF). Many AHF patients have preserved ejection fraction (HFpEF). Given the lack of evidence-based therapies in this population, we evaluated the effects of serelaxin according to EF in RELAX-AHF trial. METHODS AND RESULTS RELAX-AHF randomized 1161 AHF patients to 48-h serelaxin (30 μg/kg...
متن کاملDiuretic response in patients with acute decompensated heart failure: characteristics and clinical outcome—an analysis from RELAX-AHF
AIMS We studied the characteristics and clinical outcome related to diuretic response and the effects of serelaxin in patients hospitalized for acute heart failure (AHF). METHODS AND RESULTS RELAX-AHF was a double-blind, placebo-controlled trial, enrolling 1161 patients admitted to hospital for AHF who were randomized to 48 h i.v infusions of placebo or serelaxin (30 µg/kg per day) within 16 ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: European Journal of Heart Failure
سال: 2010
ISSN: 1388-9842
DOI: 10.1093/eurjhf/hfq132